AzTrials
AzTrials

Obesity and OverweightNCT06911073

A Study to Evaluate a Postbiotic in Supporting Weight Loss and Metabolic Health

A study testing Postbiotic in people with Obesity and Overweight, run by ResBiotic Nutrition, Inc. at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study aims to evaluate the impact of a specific oral postbiotic supplement on metabolic health in overweight adults. Read more about this study

Who is it for?
Ages 18 to 65 yearsHealthy volunteers can take part
Conditions the study is for
Obesity and Overweight
What is being tested?
Postbiotic
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
80 participants
Where
1 siteUnited States
Study dates
2 May 2025to 1 Mar 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Provide voluntary signed and dated informed consent.
  • Be in good health as determined by medical history.
  • Age between 18 and 65 yr (inclusive).
  • Body Mass Index of 25.0 - 40.0 (inclusive).
  • Subject agrees to maintain existing dietary and physical activity patterns throughout the study period.
  • Agree to refrain from other probiotic and postbiotic supplement products throughout the duration of the trial.
  • Subject is willing and able to comply with the study protocol.
  • Willing and able to agree to the requirements and restrictions of this study, be willing to give voluntary consent, be able to understand and read the questionnaires, and carry out all study-related procedures.

Who cannot join

  • History of unstable or new-onset cardiovascular/cardiorespiratory, liver, or renal conditions.
  • Alcohol abuse (more than 2 standard alcoholic drinks per day or more than 10 drinks per week) or drug abuse or dependence within the past 6 months.
  • Previous bariatric surgery.
  • Current smokers or smoking within the past month.
  • History of hyperparathyroidism or an untreated thyroid condition.
  • History of malignancy in the previous 5 years except for non-melanoma skin cancer (basal cell cancer or squamous cell cancer of the skin).
Show all 12Show fewer
  • Other known gastrointestinal or metabolic conditions that might impact nutrient absorption or metabolism, e.g., short bowel syndrome, irritable bowel syndrome (IBS), diarrheal illnesses, history of colon resection, gastroparesis, Inborn-Errors-of-Metabolism (such as PKU).
  • Chronic inflammatory condition (e.g., rheumatoid arthritis, Crohn's, ulcerative colitis, Lupus, HIV/AIDS, etc.).
  • Previous medical diagnosis of gout or fibromyalgia.
  • Pregnant women, women trying to become pregnant, women less than 120 days postpartum or nursing women. Any woman that is sexually active will have to take report their pregnancy status prior to enrolling and during the trial if they become pregnant.
  • Known sensitivity to any ingredient in the test formulations as listed in the product label.
  • Currently participating in another research study with an investigational product or have been in another research study in the past 30 days.

Trial locations and contacts

1 site in 1 country.

United States1 site

  • Able Biolabs, LLC

    Birmingham, Alabama, 35203

Other trials in United States

About this study

Official title: A Double-Blind, Randomized Placebo-Controlled Study to Evaluate a Postbiotic Supplement in Supporting Weight Loss and Metabolic Health

This study aims to evaluate the impact of a specific oral postbiotic supplement on metabolic health in overweight adults.

Read the detailed description

Obesity poses substantial health challenges contributing significantly to chronic metabolic disorders such as type 2 diabetes mellitus, cardiovascular disease, and diminished quality of life for people worldwide. Central to obesity-related metabolic dysfunction is dysregulation of appetite control, glucose homeostasis, insulin sensitivity, and systemic inflammation. Evidence indicates a strong connection between these metabolic disturbances and alterations in the gut microbiome, implicating microbiota dysbiosis as a potential target for intervention. Microbiome-based interventions underscore a promising approach in weight management and metabolic health.

Being tested
Postbiotic, Placebo
Keywords
Postbiotic, Obesity, GLP-1, Metabolic health
Medical subject headings
Obesity, Overweight

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PostbioticDietary supplement

    Also called resM™ GLP-1 Postbiotic

    Active ingredients:

    Vitamin D (as cholecalciferol) - 10 mcg Vitamin B12 (as methylcobalamin) - 200 mcg Chromium (as chromium picolinate) - 600 mcg resM™ Postbiotic (L. plantarum RSB11® HI - 16B cells) - 40 mg White mulberry (Morus alba) leaf extract - 250 mg Fenugreek (Trigonella foenum-graecum) seed extract - 200 mg

    Inactive ingredients:

    Microcrystalline cellulose, hydroxypropyl methylcellulose, magnesium stearate, silica, water, carrageenan, potassium acetate

  • PlaceboDietary supplement

    Active ingredients:

    N/A

    Inactive ingredients:

    Microcrystalline cellulose, hydroxypropyl methylcellulose, magnesium stearate, silica, water, carrageenan, potassium acetate

Study groups in NCT06911073
Study groupRoleWhat they receive
PlaceboPlacebo comparator1 capsule of placebo, taken once daily
Receives: Dietary Supplement: Placebo
Postbiotic SupplementExperimental1 capsule of 40 mg postbiotic, 450 mg herbal blend, and 810 mcg vitamins taken once daily
Receives: Dietary Supplement: Postbiotic

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. To determine the effect of resM™ on weight

    Change from baseline in weight (lb)

    Measured: 8 weeks

  2. To determine the effect of resM™ on BMI

    Change from baseline in BMI. Weight and height will be combined to report BMI in kg/m^2)

    Measured: 8 weeks

  3. To determine the effect of resM™ on food cravings

    Change in reported food cravings from baseline based on Food Craving Questionnaire Trait-reduced (FCQ-T-r) scores. The total score reflects the severity of food cravings where 90 indicates the most severe and 15 indicates the least severe.

    Measured: 8 weeks

  4. To determine the effect of resM™ on blood metabolic markers

    Change from baseline in serum fasting glucose

    Measured: 8 weeks

  5. To determine the effect of resM™ on blood metabolic markers

    Change from baseline in serum insulin levels

    Measured: 8 weeks

  6. To determine the effect of resM™ on blood metabolic markers

    Change from baseline in whole blood HbA1c (glycated hemoglobin)

    Measured: 8 weeks

Secondary outcomes (34)

  1. To determine the effect of resM™ on GLP-1

    Change from baseline in plasma active and inactive GLP-1 protein

    Measured: 8 weeks

  2. To determine the effect of resM™ on DPP-4

    Change from baseline in plasma DPP4

    Measured: 8 weeks

  3. To determine the effect of resM™ on gut microbiome

    Change from baseline in gut microbiome as assessed by 16s metagenomic sequencing on fecal samples

    Measured: 8 weeks

  4. To determine the effect of resM™ on depression

    Change from baseline in reported depression levels based on Patient Health Questionnaire 9 (PHQ-9) scores. The total score reflects the severity of depression where 1 indicates minimal depression and 27 indicates severe depression.

    Measured: 8 weeks

  5. Change in Albumin after taking resM™

    Change from baseline in Albumin

    Measured: 8 weeks

  6. Change in Albumin/Globulin ratio after taking resM™

    Change from baseline in Albumin/Globulin ratio

    Measured: 8 weeks

  7. Change in Alkaline Phosphatase after taking resM™

    Change from baseline in Alkaline Phosphatase

    Measured: 8 weeks

  8. Change in Alanine Aminotransferase (ALT) after taking resM™

    Change from baseline in Alanine Aminotransferase (ALT)

    Measured: 8 weeks

  9. Change in Aspartate Aminotransferase (AST) after taking resM™

    Change from baseline in Aspartate Aminotransferase (AST)

    Measured: 8 weeks

  10. Change in BUN/Creatinine ratio after taking resM™

    Change from baseline in blood urea nitrogen (BUN)/creatinine ratio

    Measured: 8 weeks

  11. Change in Calcium after taking resM™

    Change from baseline in calcium

    Measured: 8 weeks

  12. Change in Chloride after taking resM™

    Change from baseline in chloride

    Measured: 8 weeks

  13. Change in Glucose after taking resM™

    Change from baseline in glucose

    Measured: 8 weeks

  14. Change in Sodium after taking resM™

    Change from baseline in sodium

    Measured: 8 weeks

  15. Change in Total Bilirubin after taking resM™

    Change from baseline in total bilirubin

    Measured: 8 weeks

  16. Change in Total Protein after taking resM™

    Change from baseline in total protein

    Measured: 8 weeks

  17. Change in Urea Nitrogen after taking resM™

    Change from baseline in Urea Nitrogen

    Measured: 8 weeks

  18. Change in White Blood Cell (WBC) count after taking resM™

    Change from baseline in white blood cell (WBC) count

    Measured: 8 weeks

  19. Change in Red Blood Cell (RBC) count after taking resM™

    Change from baseline in red blood cell (RBC) count

    Measured: 8 weeks

  20. Change in Hemoglobin (Hb) after taking resM™

    Change from baseline in hemoglobin (Hb)

    Measured: 8 weeks

  21. Change in Hematocrit (Hct) after taking resM™

    Change from baseline in hematocrit (Hct)

    Measured: 8 weeks

  22. Change in Mean Corpuscular Volume (MCV) after taking resM™

    Change from baseline in mean corpuscular volume (MCV)

    Measured: 8 weeks

  23. Change in Mean Corpuscular Hemoglobin (MCH) after taking resM™

    Change from baseline in mean corpuscular hemoglobin (MCH)

    Measured: 8 weeks

  24. Change in Mean Corpuscular Hemoglobin Concentration (MCHC) after taking resM™

    Change from baseline in mean corpuscular hemoglobin concentration (MCHC)

    Measured: 8 weeks

  25. Change in Red Cell Distribution Width (RDW) after taking resM™

    Change from baseline in red cell distribution width (RDW)

    Measured: 8 weeks

  26. Change in Platelet Count after taking resM™

    Change from baseline in platelet count

    Measured: 8 weeks

  27. Change in Mean Platelet Volume (MPV) after taking resM™

    Change from baseline in Mean Platelet Volume (MPV)

    Measured: 8 weeks

  28. Change in Neutrophils after taking resM™

    Change from baseline in neutrophil count (absolute) and differential (percent)

    Measured: 8 weeks

  29. Change in Lymphocytes after taking resM™

    Change from baseline in lymphocyte count (absolute) and differential (percent)

    Measured: 8 weeks

  30. Change in Monocytes after taking resM™

    Change from baseline in monocyte count (absolute) and differential (percent)

    Measured: 8 weeks

  31. Change in Eosinophils after taking resM™

    Change from baseline in eosinophil count (absolute) and differential (percent)

    Measured: 8 weeks

  32. Change in Basophils after taking resM™

    Change from baseline in basophil count (absolute) and differential (percent)

    Measured: 8 weeks

  33. Safety - participants experiencing adverse events

    The number of participants experiencing Treatment Emergent Adverse Events (TEAEs)

    Measured: 8 weeks

  34. Safety - total adverse events

    The total number of Treatment Emergent Adverse Events (TEAEs)

    Measured: 8 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Apr 2025
  2. Study start2 May 2025
  3. Primary completion1 Mar 2026
  4. Study completion1 Mar 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Parallel groups
Model description
Randomization at 1:1 ratio of active:placebo
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
80 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06911073
Sponsor's protocol ID
ABL-032501
Status last verified
Aug 2026
First submitted
20 Mar 2025
Last updated
14 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Postbiotic in people with Obesity and Overweight, run by ResBiotic Nutrition, Inc. at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 14 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

To determine the effect of resM™ on weight (time frame: 8 weeks). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06911073.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Aug 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in